Our phase II-III-IV clinical trials unit specializes in the conduct of oncology studies in phases II, III, and IV, as well as observational research. We have a highly qualified, multidisciplinary team with extensive experience in clinical research, committed to the highest standards of scientific rigor, ethics, and regulatory compliance.

We actively participate in national and international multicenter trials, working closely with sponsors, CROs, and regulatory authorities. Our infrastructure is specifically designed to ensure the efficient and safe execution of each protocol, with dedicated areas for treatment administration, patient monitoring, and biological sample processing, all under strict adherence to ICH-GCP guidelines and current legislation.

In phase II and III trials, we contribute directly to the development of novel targeted therapies and immunotherapies, ensuring rigorous patient selection, protocol adherence, and high-quality clinical follow-up. In phase IV studies, we provide robust real-world data collection to evaluate effectiveness, pharmacovigilance, and patient-reported outcomes.

Additionally, we conduct observational studies that generate valuable evidence in routine clinical practice, complementing the insights obtained from controlled trials. Our unit is distinguished by its patient-centered approach, comprehensive data management, and a strong culture of continuous improvement.

Our mission is to accelerate access to innovative therapeutic options and contribute meaningfully to the advancement of knowledge in oncology, always prioritizing patient safety and well-being.